Glumetza

Diabetic Ketoacidosis, Congestive Heart Failure, Type 1 Diabetes + 16 more

Treatment

22 FDA approvals

20 Active Studies for Glumetza

What is Glumetza

Metformin

The Generic name of this drug

Treatment Summary

Metformin is a medication used to treat type 2 diabetes. It works by lowering blood sugar levels without causing hypoglycemia (low blood sugar). Metformin also helps reduce insulin resistance and lowers fasting insulin levels, resulting in modest weight loss. It is the drug of choice for obese type 2 diabetes patients and is used by more than 120 million people around the world. Metformin was first approved in Canada in 1972 and in the United States in 1995. It comes in regular and extended-release forms.

Metformin Hydrochloride

is the brand name

image of different drug pills on a surface

Glumetza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Metformin Hydrochloride

Metformin

2002

1263

Approved as Treatment by the FDA

Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 22 uses which include Heart Failure and Type 2 Diabetes Mellitus .

Heart Failure

Used to treat Heart Failure in combination with Dapagliflozin

Type 2 Diabetes Mellitus

Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin

Type 2 Diabetes

Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin

Chronic Kidney Disease

Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin

Renal Insufficiency

Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin

Ejection fraction decreased

Used to treat Ejection fraction decreased in combination with Dapagliflozin

Heart Failure

Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin

Kidney Failure

Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin

Ketosis

Used to treat Diabetic Ketoacidosis in combination with Saxagliptin

Diet

Used to treat Diet in combination with Dapagliflozin

Hospitalizations

Used to treat Hospitalizations in combination with Dapagliflozin

Congestive Heart Failure

Used to treat Heart Failure in combination with Dapagliflozin

Physical Activity

Used to treat Exercise in combination with Dapagliflozin

Chronic Kidney Disease (CKD)

Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin

Type 1 Diabetes Mellitus

Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin

Diabetic Ketoacidosis

Used to treat Diabetic Ketoacidosis in combination with Saxagliptin

Cardiovascular Mortality

Used to treat Cardiovascular Mortality in combination with Dapagliflozin

Diabetes Mellitus

Used to treat uncontrolled diabetes in combination with Rosiglitazone

Cardiovascular Disease

Used to treat Cardiovascular Risk in combination with Dapagliflozin

Cardiovascular Diseases

Used to treat established cardiovascular disease in combination with Dapagliflozin

Heart failure

Used to treat Heart Failure in combination with Dapagliflozin

Type 1 Diabetes

Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin

Effectiveness

How Glumetza Affects Patients

Insulin is a hormone that helps control blood sugar levels. People with type 2 diabetes have trouble responding to insulin, which leads to higher blood sugar levels. Metformin helps reduce the amount of sugar the liver makes, stops sugar from being absorbed into the body, and makes it easier for the body to use insulin. Unlike other diabetes drugs, metformin doesn't cause the body to produce more insulin. In a study of people with type 2 diabetes, those taking metformin had their blood sugar levels drop an average of 59 mg/dL, compared to an average increase of 6.3 mg/dL in those taking a placebo

How Glumetza works in the body

Metformin works in several ways to lower blood sugar. It reduces the amount of glucose your liver makes, blocks glucose from being absorbed by your intestines, and increases the sensitivity of your body to insulin. Metformin is taken up by liver cells, where it blocks a key enzyme and increases the ratio of AMP to ATP. This helps activate AMPK, an enzyme that regulates glucose metabolism. AMPK then stops fat synthesis and helps fat break down in the liver, making it more sensitive to insulin. Metformin also stimulates glucose metabolism in the small intestines and increases the production of GLP-1, which helps reduce

When to interrupt dosage

The suggested amount of Glumetza is contingent upon the identified condition, including Diet, inadequate response to metformin and Diabetic Ketoacidosis. The dosage changes in accordance with the mode of delivery (e.g. Oral or Tablet - Oral) noted in the table beneath.

Condition

Dosage

Administration

Cardiovascular Diseases

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

inadequate response to metformin

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Insulin Resistance

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Renal Insufficiency

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Diabetes Mellitus

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Congestive Heart Failure

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Type 2 Diabetes

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Chronic Kidney Disease

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Diabetic Ketoacidosis

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Physical Activity

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Kidney Failure

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Diet

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Hospitalizations

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Heart Failure

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Type 1 Diabetes

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Polycystic Ovarian Syndrome

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Cardiovascular Disease

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Cardiovascular Mortality

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Ejection fraction decreased

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral

Warnings

Glumetza Contraindications

Condition

Risk Level

Notes

Liver Failure

Do Not Combine

Renal Insufficiency

Do Not Combine

Heart Arrest

Do Not Combine

Diabetic Ketoacidosis

Do Not Combine

Operative Surgery

Do Not Combine

Metabolic acidosis

Do Not Combine

Heart Failure

Do Not Combine

Renal Insufficiency

Do Not Combine

kidney function unknown

Do Not Combine

Hypovolemic Shock

Do Not Combine

serum creatinine above upper limit for age range

Do Not Combine

ethanol

Do Not Combine

Acute Coryza

Do Not Combine

Hypoxemia

Do Not Combine

Liver Failure

Do Not Combine

Acidosis, Lactic

Do Not Combine

Diabetic Ketoacidosis

Do Not Combine

Renal Insufficiency

Do Not Combine

Renal Insufficiency, Chronic

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Metformin may interact with Pulse Frequency

There are 20 known major drug interactions with Glumetza.

Common Glumetza Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Metformin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Metformin.

Topotecan

Major

The excretion of Topotecan can be decreased when combined with Metformin.

Abacavir

Minor

Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.

Aclidinium

Minor

Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Glumetza Toxicity & Overdose Risk

The toxic dose of Metformin in rats is 1 gram/kg when given orally, 500 milligrams/kg when given through the abdomen, and 300 milligrams/kg when given through the skin. Similarly, in mice, the toxic dose is 1,450 milligrams/kg when given orally, 420 milligrams/kg when given through the abdomen, and 225 milligrams/kg when given through the skin. Metformin decreases the liver's uptake of lactate, which can lead to lactic acidosis in rare cases. Risk factors for metformin-associated lactic acidosis include kidney problems

image of a doctor in a lab doing drug, clinical research

Glumetza Novel Uses: Which Conditions Have a Clinical Trial Featuring Glumetza?

At present, 346 active clinical trials are investigating Glumetza's capacity to treat Type 2 Diabetes, Type 1 Diabetes and an inadequate response to metformin treatments.

Condition

Clinical Trials

Trial Phases

Chronic Kidney Disease

97 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1

Cardiovascular Diseases

0 Actively Recruiting

Congestive Heart Failure

178 Actively Recruiting

Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 4, Phase 3

Type 1 Diabetes

112 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Early Phase 1, Phase 4

Cardiovascular Disease

25 Actively Recruiting

Not Applicable, Early Phase 1, Phase 3, Phase 2

Type 2 Diabetes

162 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Kidney Failure

39 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Physical Activity

25 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Insulin Resistance

0 Actively Recruiting

Renal Insufficiency

0 Actively Recruiting

Cardiovascular Mortality

0 Actively Recruiting

Ejection fraction decreased

0 Actively Recruiting

Hospitalizations

1 Actively Recruiting

Not Applicable

Diabetic Ketoacidosis

2 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Polycystic Ovarian Syndrome

7 Actively Recruiting

Not Applicable, Phase 1

inadequate response to metformin

0 Actively Recruiting

Heart Failure

0 Actively Recruiting

Diet

4 Actively Recruiting

Not Applicable, Phase 1

Diabetes Mellitus

0 Actively Recruiting

Glumetza Reviews: What are patients saying about Glumetza?

5

Patient Review

5/6/2013

Glumetza for Prevention of Type 2 Diabetes Mellitus

I took 1 500mg pill for 2 days and had the worst nausea, gas and stomach pains!!! I can't take it again. Had a similar, but less severe experience with Metformin ER.

5

Patient Review

3/19/2014

Glumetza for Prevention of Type 2 Diabetes Mellitus

Switching to gourmet metformin from regular helped me a lot with my diarrhea problem. As long as I eat minimal amounts of carbs, it works great with no side effects. If I don't get enough or the right kind of carbs, though, I have some nasty gastric issues.

5

Patient Review

10/16/2013

Glumetza for Type 2 Diabetes Mellitus

Glumetza ER has alleviated the severe diarrhea I was experiencing with base Glumetza. 1000mg twice a day (morning and night) is my current dosage.

5

Patient Review

10/29/2015

Glumetza for Type 2 Diabetes Mellitus

I was on Metformin (2 x 500 mg per day) for 4 1/2 years. Gradually, nausea and heartburn started and increased until they were unbearable. I learned about Glumetza 1000 mg and started it in April 2015; the side effects disappeared within a few days.

5

Patient Review

5/12/2016

Glumetza for Type 2 Diabetes Mellitus

Glumetza was great for my stomach, but unfortunately didn't help lower my blood sugar as much. The cost increase was also a big factor in why I had to switch back to Metformin.

4.3

Patient Review

4/21/2013

Glumetza for Type 2 Diabetes Mellitus

I was taking this medication for five weeks, but I'm quitting today because it made me too anxious.

4.3

Patient Review

8/13/2015

Glumetza for Type 2 Diabetes Mellitus

Glumetza has been the best for my stomach, but it is way too expensive. I've been spending $353/month and it just jumped to over $3000!

3.7

Patient Review

1/19/2013

Glumetza for Type 2 Diabetes Mellitus

3.7

Patient Review

8/9/2014

Glumetza for Type 2 Diabetes Mellitus

Glumetza 500XR has worked much better for me than Metformin 1000mg. I no longer experience gas or gastric issues, and my neuropathy pain has decreased significantly.

3

Patient Review

4/13/2013

Glumetza for Type 2 Diabetes Mellitus

I had a really bad experience with this drug. I was taking generic Metformin and my doctor switched me to the name brand Glumetza in an effort to stop the diarrhea I was experiencing. Once I paid $800 for a month supply and gave it a try, the diarrhea got even worse!

3

Patient Review

4/27/2013

Glumetza for Type 2 Diabetes Mellitus

I gained weight while on this medication, which was frustrating. Additionally, it didn't do much to help control my blood sugar levels. Finally, the cost of the medication was quite high.

3

Patient Review

11/14/2014

Glumetza for Type 2 Diabetes Mellitus

My blood sugar isn't as low as it used to be, but this treatment is still helpful.

2.7

Patient Review

9/14/2013

Glumetza for Type 2 Diabetes Mellitus

This medication unfortunately gave me diarrhea, itching, and blisters.

2.3

Patient Review

4/5/2013

Glumetza for Type 2 Diabetes Mellitus

This was working well for me at first, but it's not effective anymore. My blood sugar is now over 200 when I fast.

2.3

Patient Review

7/19/2013

Glumetza for Prevention of Type 2 Diabetes Mellitus

Metformin made me so sick that I couldn't keep food down. In contrast, this pill didn't have any adverse reactions for me and I actually lost 5 pounds in the first month without changing anything else. The only downside is that it's SO expensive.

2

Patient Review

12/17/2012

Glumetza for Type 2 Diabetes Mellitus

1

Patient Review

8/26/2013

Glumetza for Prevention of Type 2 Diabetes Mellitus

My insulin levels were really high when I took this medication, way higher than what the doctor wanted. The side effects were also really bad - stomach aches and diarrhea - and made me feel weak and tired.

1

Patient Review

3/8/2013

Glumetza for Type 2 Diabetes Mellitus

This drug is expensive and unfortunately ineffective for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about glumetza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Glumetza?

"The medication GLUMETZA, which is an extended release tablet of metformin hydrochloride, is used to help manage type 2 diabetes. This medication is not related chemically or pharmacologically to any other classes of oral antihyperglycemic agents."

Answered by AI

Why is Glumetza better than metformin?

"Compared to metformin immediate-release doses that are equal in strength, using Glumetza results in the same amount of the drug being distributed throughout the body. However, the peak plasma concentration will be 35% higher. When doses of Glumetza ranging from 500 mg to 2500 mg were given, the total drug exposure and peak plasma concentration increased, but not in proportion to the dose."

Answered by AI

Is Glumetza the same as metformin?

"Glumetza is a MOD metformin product that uses Acuform and Smartcoat, two advanced delivery systems. These delivery systems contain a substance that allows the metformin tablet to stay in the stomach for an extended period of time."

Answered by AI

What is Glumetza used for?

"The drug is used to treat patients with type 2 diabetes by controlling high blood sugar levels, which can prevent complications such as kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke."

Answered by AI

Clinical Trials for Glumetza

Image of Faculty of Health Sciences in Winnipeg, Canada.

Treatment for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Our previous studies demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Our preliminary studies in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. We propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
New This Month

Faculty of Health Sciences

Image of Columbia University in New York, United States.

MediBeacon Transdermal GFR System for Heart Failure

18+
All Sexes
New York, NY

The goal of this clinical trial is to evaluate the accuracy and feasibility of transdermal glomerular filtration rate (tGFR) assessment using relmapirazin (Lumitrace) and the MediBeacon tGFR system compared to plasma clearance measurement of GFR in adults with heart failure. The main question it aims to answer is the comparison of the transdermal-derived GFR for each participant using the MediBeacon tGFR to their nGFRBSA measurement. Participants will participate in a Screening visit that will take place within 15 days of the scheduled administration of Lumitrace and iohexol. On dosing day, participants will have the tGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. Following an injection of Lumitrace and iohexol and the initiation of GFR assessments, participants will be followed at the study center for 10-24 hours. All participants will participate in a follow-up phone call approximately 7 days after the last exposure to Lumitrace and iohexol. Researchers will analyze the results to compare the tGFR values to the nGFRBSA measurements for each participant.

Waitlist Available
Has No Placebo

Columbia University

Richard B Dorshow, PhD

MediBeacon

Image of ProSciento, Inc. in Chula Vista, United States.

Portal Insulin U-500 for Type 1 Diabetes

18 - 60
All Sexes
Chula Vista, CA

The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer are: Is the drug safe and tolerable when administered intraperitoneally? How fast is it absorbed, and how long does it take to act? Researchers will compare the investigational product (PI-U500) with Humulin R U500 administered intraperitoneally and Lyumjev U100 administered subcutaneously. Participants will undergo a 12-hour clamp procedure in which their blood glucose will be maintained stable via glucose infusion at variable rates after a single intraperitoneal injection of the insulin formulation.

Phase 1
Recruiting

ProSciento, Inc.

Portal Diabetes, Inc.

Have you considered Glumetza clinical trials?

We made a collection of clinical trials featuring Glumetza, we think they might fit your search criteria.
Go to Trials
Image of Mass General Brigham in Boston, United States.

Clinical Decision Support Tool for Heart Failure

18 - 85
All Sexes
Boston, MA

This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinics at Mass General Brigham. For eligible heart failure encounters, the CDS tool reviews existing electronic health record (EHR) data, including diagnoses, medications, vital signs, laboratory results, and recent notes, and generates brief, clinician-facing messages suggesting opportunities to initiate or optimize GDMT and highlighting relevant safety considerations. Messages are delivered to cardiology providers via Epic InBasket and/or institutional email prior to scheduled visits. The tool is advisory only and cannot place orders or change medications automatically; all treatment decisions remain at the discretion of the treating clinician and patient. Cardiology providers are assigned at the provider/clinic level to early implementation of the CDS tool versus usual care (no messages) during the initial phase. The primary outcome is GDMT optimization within 30 days of an index visit. Secondary outcomes include feasibility of CDS generation and delivery and a 30-day safety composite (e.g., heart failure hospitalization, acute kidney injury, hyperkalemia, hypotension or bradyarrhythmia plausibly related to GDMT).

Waitlist Available
Has No Placebo

Mass General Brigham

Image of International Diabetes Center in Minneapolis, United States.

Sotagliflozin for Type 1 Diabetes

18 - 75
All Sexes
Minneapolis, MN

The goal of this clinical trial is to develop and evaluate a novel diabetes ketoacidosis risk mitigation strategy to support the safe use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy in participants with type 1 diabetes (T1D) and mild to moderate chronic kidney disease (CKD). The main objectives of this study are to: 1. Evaluate how ketone metrics differ between participants with mild to moderate chronic kidney disease and those with normal renal function in three time periods. 2. Identify potentially modifiable ketosis risk factors. 3. Use continuous glucose monitoring (CGM) and continuous ketone monitoring (CKM) data prior to and following treatment to determine ketosis risk factors and gain knowledge to further refine reporting of risk factors. 4. Gather information on how participants and clinicians like and use the CGM/CKM reports. Participants will be asked to: * Meet with study investigators to determine if they are eligible * Sign written informed consent * Take a pregnancy test, if applicable * Have blood taken to assess kidney function and hemoglobin A1c * Take the study medication, following the study team instructions * Wear the study provided sensor throughout participation. * Complete 5 in person visits, and 11 phone check ins over a nine-month period * Provide feedback on the usefulness of CGM/CKM reports

Phase 2
Waitlist Available

International Diabetes Center

Richard Bergenstal, MD

Have you considered Glumetza clinical trials?

We made a collection of clinical trials featuring Glumetza, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Kaiser Permanente Northern California (KPNC) in Pleasanton, United States.

Deprescribing Beta-Blockers for Diastolic Heart Failure

18+
All Sexes
Pleasanton, CA

The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life. Participants will be randomly assigned to one of two groups: Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses. Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules. All participants will: * Take study medicine for about 4 months * Have their blood pressure and heart rate monitored * Complete regular phone calls and questionnaires about how they are feeling This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.

Phase 4
Waitlist Available

Kaiser Permanente Northern California (KPNC)

Parag Goyal, MD, MSc

Have you considered Glumetza clinical trials?

We made a collection of clinical trials featuring Glumetza, we think they might fit your search criteria.
Go to Trials